Morphic Holding Inc MORF

NAS: MORF | ISIN: US61775R1059   21:00
30,54 USD (+2,14%)
(+2,14%)   21:00

3 april 2024 · Ademi LLP Investigates Claims of Securities Fraud against Morphic Holding, Inc. · Persbericht

25 oktober 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF) · Persbericht

18 oktober 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF) · Persbericht

13 oktober 2023 · MORF INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm · Persbericht

9 oktober 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Morphic Holding, Inc. (MORF) · Persbericht

3 maart 2021 · Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering · Persbericht

1 maart 2021 · Morphic Therapeutic Announces Proposed Public Offering · Persbericht

1 maart 2021 · Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057 · Persbericht

22 februari 2021 · Morphic Therapeutic to Host Analyst and Investor Call on March 1, 2021 · Persbericht

16 februari 2021 · Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference · Persbericht

5 januari 2021 · Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program · Persbericht

Mijn selecties